0001104659-21-112264.txt : 20210902 0001104659-21-112264.hdr.sgml : 20210902 20210902091913 ACCESSION NUMBER: 0001104659-21-112264 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210827 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210902 DATE AS OF CHANGE: 20210902 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Osmotica Pharmaceuticals plc CENTRAL INDEX KEY: 0001739426 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38709 FILM NUMBER: 211231843 BUSINESS ADDRESS: STREET 1: 400 CROSSING BOULEVARD CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 9088091300 MAIL ADDRESS: STREET 1: 400 CROSSING BOULEVARD CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: Osmotica Pharmaceuticals Ltd DATE OF NAME CHANGE: 20180502 8-K 1 tm2126709d1_8k.htm FORM 8-K
0001739426 false 00-0000000 0001739426 2021-08-27 2021-08-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 27, 2021

 

Osmotica Pharmaceuticals plc

 

Commission File Number: 001-38709

 

Ireland

(State or other jurisdiction
of incorporation)

Not Applicable

(IRS Employer
Identification No.)

   

400 Crossing Boulevard
Bridgewater, NJ

(Address of principal executive offices)

 

08807

(Zip Code)

 

(908) 809-1300

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Ordinary Shares   OSMT   Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

 

 

 

 

 

Item 2.01 Completion of Acquisition or Disposition of Assets.

 

On August 27, 2021, Osmotica Pharmaceuticals plc (the “Company”), and certain of its wholly owned subsidiaries, completed the previously disclosed divestiture of the Company’s legacy products business (the “Legacy Business”). The divestiture was consummated through the sale of the equity interests of certain of the Company’s indirect subsidiaries and other assets comprising the Legacy Business to Acella Holdings, LLC (the “Purchaser”), an affiliate of Alora Pharmaceuticals, LLC (“Alora”), for approximately $111 million in cash, subject to customary post-closing adjustments, and the contingent right to receive post-closing payments of up to an additional $60 million upon the achievement of certain milestones related to continued market exclusivity for a specified period of time or net sales volume of certain products of the Legacy Business following the closing of the divestiture.

 

The foregoing description of the divestiture does not purport to be complete and is qualified in its entirety by reference to the full text of the Purchase and Sale Agreement among the Company, certain of its wholly owned subsidiaries, the Purchaser and Alora, dated June 24, 2021, a copy of which was filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 30, 2021, the full text of which is incorporated herein by reference.

 

Item 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.

 

As described in Item 1.01 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 30, 2021, which is incorporated into this Item 2.04 by reference, in connection with the Company’s entry into the Purchase and Sale Agreement, it entered into a Contingent Amendment Agreement, dated as of June 24, 2021, among the Company, Osmotica Pharmaceutical Corp and Valkyrie Group Holdings, Inc. (the “Borrowers”), certain other subsidiaries of the Company, and all of the lenders party to the Borrower’s existing credit agreement (the “Credit Agreement Amendment”). The Credit Agreement Amendment provided, among other things, that (i) the Company would contribute substantially all of its cash on hand to the Borrowers upon closing of the divestiture referenced in Item 2.01 above and (ii) the Borrowers would make payments to reduce the outstanding term loan balance to $30 million upon closing of the divestiture. Accordingly, in connection with the closing of the divestiture referenced in Item 2.01 above, the Borrowers repaid approximately $179 million aggregate principal amount of their outstanding term loan balance on August 27, 2021. The maturity of the $30 million of remaining term loans is November 21, 2021.

 

The foregoing description of the Credit Agreement Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Credit Agreement Amendment dated June 24, 2021, a copy of which was filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 30, 2021, the full text of which is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(b) Pro forma financial information.

 

The unaudited pro forma condensed consolidated financial statements of the Company giving effect to the Transaction discussed in Item 2.01 above are filed as Exhibit 99.1 hereto and incorporated herein by reference.

 

(d) Exhibits

 

Exhibit
No.		   Description
99.1   Unaudited Pro Forma Condensed Consolidated Financial Statements of Osmotica Pharmaceuticals plc
     
104   The cover page from this Current Report on Form 8-K of Osmotica Pharmaceuticals plc, formatted in Inline XBRL and included as Exhibit 101

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date:         September 2, 2021   Osmotica Pharmaceuticals plc
   
  By: /s/ Brian Markison
    Brian Markison
    Chief Executive Officer

 

 

 

 EX-99.1 2 tm2126709d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION

 

On August 27, 2021 (the “Closing”), Osmotica Pharmaceuticals plc (the “Company”) completed the previously announced sale of its legacy products business (the “Legacy Business”) pursuant to the Purchase and Sale Agreement (the “Purchase Agreement”) dated June 24, 2021 with Acella Holdings, LLC (the “Purchaser”) and Alora Pharmaceuticals, LLC, an affiliate of the Purchaser. Pursuant to the Purchase Agreement, the Purchaser acquired the Legacy Business through the sale of the equity interests of certain of the Company’s indirect subsidiaries and other assets comprising the Legacy Business for total cash consideration of approximately $111 million, subject to post-closing adjustments (the “Transaction”). The Company and the Purchaser will each provide the other with certain transition services related to the Legacy Business for a period of up to twelve months from the Closing. An additional $60 million may be payable to the Company upon the achievement of certain milestones related to continued market exclusivity for a specified period of time or net sales volume of certain products of the Legacy Business following the Closing.

 

In connection with the Transaction, Osmotica Pharmaceutical Corp. and Valkyrie Group Holdings, Inc., each a subsidiary of the Company (collectively, the “Borrowers”), along with certain other subsidiaries of the Company, entered into a Contingent Amendment Agreement, dated as of June 24, 2021 (the “Credit Agreement Amendment”), with all of the lenders party to the Borrowers’ existing credit agreement, which amended the Borrowers’ existing credit agreement to permit the transactions contemplated by the Purchase Agreement. The Credit Agreement Amendment further provided that (i) the Borrowers would make payments to reduce the outstanding term loan balance to $30 million upon the Closing, (ii) the Borrowers’ revolving credit facilities would be terminated (50% upon signing of the Credit Agreement Amendment and the remaining 50% upon the Closing), (iii) the maturity of the term loans will be shortened to the earlier of (x) 120 days after the Closing and (y) 150 days after signing of the Credit Agreement Amendment, (iv) the Company would contribute substantially all of its cash on hand to the Borrowers upon closing of the Transaction and (v) the Borrowers would pay fees to the lenders based upon the outstanding principal balance of the term loans at certain times after the Closing.

 

The Legacy Business met the criteria set forth in Accounting Standards Codification 205-20, Presentation of Financial Statements – Discontinued Operations (“ASC 205-20”). As a result, the results of operations of the Legacy Business have been classified as discontinued operations in the interim consolidated statements of operations presented in the financial statements included in the Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021.

 

The unaudited pro forma condensed consolidated financial statements have been prepared in accordance with Regulation S-X Article 11, Pro Forma Financial Information (“Article 11”). The transaction accounting adjustments are described in the notes to the unaudited condensed consolidated pro forma financial statements.

 

The transaction accounting adjustments are based on available information and assumptions that the Company’s management believes are reasonable. However, such adjustments are estimates and actual experience may differ from expectations.

 

The unaudited pro forma condensed consolidated balance sheet has been prepared giving effect to the Transaction as if it had occurred on June 30, 2021, and the unaudited pro forma condensed consolidated statements of operations for the years ended December 31, 2020 and 2019 have been prepared giving effect to the Transaction as if it had occurred on January 1, 2019.

 

The unaudited pro forma condensed consolidated financial statements are for illustrative purposes only, and do not reflect what the Company’s results of operations would have been had the Transaction occurred on the dates indicated, are not necessarily indicative of the Company’s future results of operations and do not reflect all actions that may be taken by the Company after the Transaction.

 

1 

 

 

The unaudited pro forma condensed consolidated financial statements and the accompanying notes should be read in conjunction with the historical financial statements and notes thereto of the Company, as presented in its Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission (“SEC”) on March 30, 2021, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed with the SEC on August 16, 2021.

 

The unaudited pro forma condensed consolidated financial information includes information, statements, and assumptions that are or may be considered “forward-looking” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally may be identified by the use of words such as “may,” “should,” “will,” “expect,” “anticipate,” “continue,” “estimate,” “project,” “believe,” “plan” or similar expressions. Statements that describe objectives, plans, or goals also are forward-looking statements. These forward-looking statements involve risks and uncertainties, and actual results may differ materially from those contemplated by the forward-looking statements due to, among other, the risks and uncertainties described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, and in the Company’s subsequent SEC filings. For any forward-looking statements contained herein, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and the Company undertakes no obligation to update publicly or revise any forward-looking statements in light of the new information or future events, except as required by law.

 

2 

 

 

Unaudited Pro Forma Condensed Consolidated Balance Sheet

As of June 30, 2021

(in thousands, except share and per share data)

 

       Transaction Accounting Adjustments        
​      Discontinued            
       Operations of            
​      Legacy Business   Pro Forma      Pro Forma 
​  As Reported   (a)   Adjustments   Notes  Osmotica 
Assets                       
Current assets:                       
Cash and cash equivalents  $99,777   $104,000   $(186,060)  (b) (d)  $17,717 
Trade accounts receivable, net   645    -    -       645 
Inventories, net   1,020    -    -       1,020 
Prepaid expenses and other current assets   13,908    -    -       13,908 
Assets held for sale   134,133    (134,133)   -       - 
Total current assets   249,483    (30,133)   (186,060)      33,290 
Property, plant and equipment, net   848    -    -       848 
Operating lease assets   1,344    -    -       1,344 
Intangibles, net   27,210    -    -       27,210 
Goodwill   55,847    -    -    (c)   55,847 
Other non-current assets   279    -    -       279 
Total assets  $355,011   $(30,133)  $(186,060)     $118,818 
Liabilities and Shareholders' Equity                       
Current liabilities:                       
Trade accounts payable  $1,549    -   $-      $1,549 
Accrued liabilities   13,420    -    -       13,420 
Current portion of obligation under finance leases   7    -    -       7 
Current portion of lease liability   1,003    -    -       1,003 
Current portion of long-term debt, net of deferred financing costs   214,720    -    (184,791)  (d)   29,929 
Income taxes payable - current portion   138    -    -       138 
Liabilities held for sale   34,674    (34,674)   -       - 
Total current liabilities   265,511    (34,674)   (184,791)      46,046 
Long-term portion of obligation under finance leases   -    -    -       - 
Long-term portion of lease liability   434    -    -       434 
Income taxes payable - long term   1    -    -       1 
Deferred taxes   611    -    -       611 
Total liabilities   266,557    (34,674)   (184,791)      47,092 
Shareholders' equity:                       
Ordinary shares ($0.01 nominal value 400,000,000 shares authorized, 62,719,131 shares issued and outstanding)   628    -    -       628 
Preferred shares ($0.01 nominal value 40,000,000 shares authorized, no shares issued and outstanding)   -    -    -       - 
Euro deferred shares (€1.00 nominal value 25,000 shares authorized, no shares issued and outstanding)   -    -    -       - 
Additional paid in capital   550,004    -    -       550,004 
Accumulated (deficit) / equity   (479,949)   4,541    (1,269)  (e) (d)   (476,677)
Accumulated other comprehensive loss   (2,229)   -    -       (2,229)
Total shareholders' equity   68,454    4,541    (1,269)      71,726 
Total liabilities and shareholders' equity  $355,011   $(30,133)  $(186,060)     $118,818 

 

Refer to accompanying Notes to Unaudited Pro Forma Condensed Consolidated Financial Statements

 

3 

 

 

 

Unaudited Pro Forma Condensed Consolidated Statement of Operations and Comprehensive Income

For the six months ended June 30, 2021

(in thousands, except share and per share data)

 

​      Transaction Accounting
Adjustments		         
​      Discontinued             
       Operations of             
       Legacy
Business		   Pro Forma       Pro Forma 
​  As Reported   (a)   Adjustments   Notes   Osmotica 
Net product sales  $2,255   $-   $-        $2,255 
Royalty revenue   190    -    -         190 
Licensing and contract revenue   10,000    -    -         10,000 
Total revenues   12,445    -    -         12,445 
Cost of goods sold (inclusive of amortization of intangibles)   1,388    -    -         1,388 
Gross profit   11,057    -    -         11,057 
Selling, general and administrative expenses   38,002    -    -         38,002 
Research and development expenses   4,256    -    -         4,256 
Impairment of intangibles   7,880    -    -         7,880 
Total operating expenses   50,138    -    -         50,138 
Gain on sale of product rights, net   5,636    -    -         5,636 
Operating (loss) / income   (33,445)   -    -         (33,445)
Interest expense and amortization of debt discount   1,015    -    (79)   (f)    936 
Other non-operating (gain) / loss   1,193    -    9    (g)    1,202 
Total other non-operating expense   2,208    -    (70)        2,138 
(Loss) / gain before income taxes   (35,653)   -    (70)        (35,583)
Income tax expense/(benefit)   90         -         90 
Net and other comprehensive loss / income   (35,743)   -    (70)        (35,673)
Income from discontinued operations, net of tax   8,401    (8,401)   -         - 
Net and other comprehensive loss / income  $(27,342)  $(8,401)  $(70)       $(35,673)
Loss per share attributable to shareholders                         
Basic and Diluted  $(0.44)                 $(0.57)
Weighted average shares basic and diluted                         
Basic and Diluted   62,723,011                   62,723,011 

 

Refer to accompanying Notes to Unaudited Pro Forma Condensed Consolidated Financial Statements

 

4 

 

 

Unaudited Pro Forma Condensed Consolidated Statement of Operations and Comprehensive Loss

For the Year-Ended December 31, 2020

(in thousands, except share and per share data)

 

​      Transaction Accounting
Adjustments		         
​      Discontinued             
       Operations of             
       Legacy
Business		   Pro Forma       Pro Forma 
​  As Reported   (a)   Adjustments   Notes   Osmotica 
Net product sales  $145,850   $(143,908)  $-        $1,942 
Royalty revenue   4,107    (3,287)   -         820 
Licensing and contract revenue   27,927    (2,927)   -         25,000 
Total revenues   177,884    (150,122)   -         27,762 
Cost of goods sold (inclusive of amortization of intangibles)   74,480    (71,187)   -         3,293 
Gross profit   103,404    (78,935)   -         24,469 
Selling, general and administrative expenses   81,961    (9,782)   -         72,179 
Research and development expenses   19,696    (6,353)   -         13,343 
Impairment of intangibles   72,183    (43,273)   -         28,910 
Total operating expenses   173,840    (59,408)   -         114,432 
Operating (loss) / income   (70,436)   (19,527)   -         (89,963)
Interest expense and amortization of debt discount   14,396    (10,301)   120    (f)    4,215 
Other non-operating (gain)/loss   (546)   594    238    (g)    286 
Total other non-operating expense   13,850    (9,707)   358         4,501 
(Loss) / income before income taxes   (84,286)   (9,820)   (358)        (94,464)
Income tax benefit   4,697    1,085    82         5,864 
Net and other comprehensive (loss) / income  $(79,589)  $(8,735)  $(276)       $(88,600)
Loss per share attributable to shareholders                         
Basic and Diluted  $(1.31)                 $(1.46)
Weighted average shares basic and diluted                         
Basic and Diluted   60,652,999                   60,652,999 

 

Refer to accompanying Notes to Unaudited Pro Forma Condensed Consolidated Financial Statements

 

5 

 

 

Unaudited Pro Forma Condensed Consolidated Statement of Operations and Comprehensive Loss

For the Year-Ended December 31, 2019

(in thousands, except share and per share data)

 

​      Transaction Accounting
Adjustments		         
​      Discontinued             
       Operations of             
       Legacy
Business		   Pro Forma       Pro Forma 
​  As Reported   (a)   Adjustments   Notes   Osmotica 
Net product sales  $235,472   $(235,033)  $-        $439 
Royalty revenue   3,641    (2,878)   -         763 
Licensing and contract revenue   918    (918)   -         - 
Total revenues   240,031    (238,829)   -         1,202 
Cost of goods sold (inclusive of amortization of intangibles)   111,630    (108,508)   -         3,122 
Gross profit   128,401    (130,321)   -         (1,920)
Selling, general and administrative expenses   93,030    (10,382)   -         82,648 
Research and development expenses   32,319    (7,757)   -         24,562 
Impairment of intangibles   283,747    (266,017)   -         17,730 
Total operating expenses   409,096    (284,156)   -         124,940 
Operating loss   (280,695)   153,835    -         (126,860)
Interest expense and amortization of debt discount   18,211    (12,197)   151    (f)    6,165 
Other non-operating (gain)/loss   (884)   156    3,125    (g)    2,397 
Total other non-operating expense   17,327    (12,041)   3,276         8,562 
Loss before income taxes   (298,022)   165,876    (3,276)        (135,422)
Income tax benefit   27,121    (20,694)   730         7,157 
Net loss  $(270,901)  $145,182   $(2,546)       $(128,265)
Other comprehensive loss, net                         
Change in foreign currency translation adjustment   (383)   -    -         (383)
Comprehensive loss  $(271,284)  $145,182   $(2,546)       $(128,648)
Loss per share attributable to shareholders                         
Basic and Diluted  $(5.17)                 $(2.45)
Weighted average shares basic and diluted                         
Basic and Diluted   52,367,444                   52,367,444 

 

Refer to accompanying Notes to Unaudited Pro Forma Condensed Consolidated Financial Statements

 

6 

 

 

NOTES TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION

(In thousands, except per share information)

 

Note 1. Basis of Presentation

 

The unaudited pro forma condensed consolidated financial statements are based on the Company’s historical consolidated financial statements as adjusted to give effect to the transaction accounting adjustments in accordance with U.S. generally accepted accounting principles (“GAAP”) to reflect the disposition of the Legacy Business and related transactions.

 

The pro forma condensed consolidated financial statements do not necessarily reflect what the consolidated Company’s financial condition or results of operations would have been had the Transaction occurred on the dates indicated. They also may not be useful in predicting the future financial condition and results of operations of the Company. The actual financial position and results of operations may differ significantly from the amounts reflected herein due to a variety of factors.

 

Note 2. Transaction Accounting Adjustments

 

The transaction accounting adjustments included in the unaudited pro forma condensed consolidated financial statements related to the Transaction include:

 

(a)Reflects the disposition of the operations, assets, liabilities and equity of the Legacy Business in accordance with ASC 205 and the expected net cash proceeds therefrom.

 

(b)Net proceeds received less estimated transaction costs has been included as an adjustment to cash on the unaudited pro forma condensed consolidated balance sheet as follows (in thousands):

 

Cash proceeds of the sale (1)  $111,000 
Less: Estimated transaction costs (2)   7,000 
Total net proceeds less estimated transaction costs  $104,000 

 

(1)Only cash proceeds are considered in the estimated gain calculation. The potential additional contingent milestone payments up to $60 million would be recognized when the contingencies are achieved and the payments are realized or realizable.

 

(2)Estimated transaction closing costs include incremental costs that are directly attributable to the sale but not reflected in the accompanying unaudited pro forma condensed consolidated statements of operations. These costs are comprised primarily of professional fees (e.g., legal, banking and accounting) that are directly related to the sale of the Legacy Business.

 

(c)Amount reflects the preliminary estimated adjustment to goodwill as a result of the Legacy Business divestiture. The Company is organized in one reporting unit. As a portion of the Company’s reporting unit is disposed of in this Transaction, the Company preliminarily assigned goodwill based on the estimated relative fair value of the reporting unit being disposed and the portion of the reporting unit remaining.

 

Based on the estimated relative fair value approach, the Company preliminarily assigned approximately 45% of the outstanding goodwill balance to the Legacy Business.

 

7 

 

 

NOTES TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION

(In thousands, except per share information)

 

(d)The Company had total outstanding indebtedness of approximately $214.7 million (net of $1.3 million deferred financing costs) as of June 30, 2021 and had unused commitments of $25.0 million under the senior secured credit facilities. The pro forma adjustment to debt includes the following amounts (in thousands):

 

Total repayment of credit facilities  $186,060 
Less: Accelerated amortization of debt issuance costs   1,269 
Pro forma adjustment to debt  $184,791 

 

(e)The pro forma gain on disposition is based on the Legacy Business’s historical balance sheet information as of June 30, 2021. The actual gain or loss on disposal will be based on the Legacy Business’s historical balance sheet information as of the closing date and may differ significantly. The pro forma gain on disposition has not been reflected in the unaudited pro forma condensed consolidated statements of operations as this amount pertains to discontinued operations and does not reflect the impact on income from continuing operations. The pro forma gain is calculated as follows (in thousands):

 

Total net proceeds less estimated transaction costs  $104,000 
Less: Legacy Business net assets   99,459 
Pro forma gain on disposition (1)  $4,541 

 

(1)Using facts and circumstances available as of the date of this Current Report on Form 8-K, the Company expects no taxable gain on the sale.

 

(f)Reflects the change in estimated interest expense and amortization of debt issuance costs incurred from the estimated payments to reduce the outstanding term loan balance to $30 million upon closing of the Transaction and the reduction in the maturity of the term loans. The interest along with the associated amortization of debt issuance costs have been included in discontinued operations. The pro forma adjustment to interest expense is presented as if the Transaction and prepayment of debt had occurred on January 1, 2019.

 

(g)Represents the loss on extinguishment of debt and write-off of unamortized debt issuance costs related to debt modifications as if the proceeds of the Transaction had been used for the required prepayment of the Company’s term loans as of January 1, 2019.

 

8 

 

 EX-101.SCH 3 osmt-20210827.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 osmt-20210827_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 osmt-20210827_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 tm2126709d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001739426 2021-08-27 2021-08-27 iso4217:USD shares iso4217:USD shares 0001739426 false 00-0000000 8-K 2021-08-27 Osmotica Pharmaceuticals plc 001-38709 L2 400 Crossing Boulevard Bridgewater NJ 08807 908 809-1300 false false false false Ordinary Shares OSMT NASDAQ true true XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Aug. 27, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 27, 2021
Entity File Number 001-38709
Entity Registrant Name Osmotica Pharmaceuticals plc
Entity Central Index Key 0001739426
Entity Tax Identification Number 00-0000000
Entity Incorporation, State or Country Code L2
Entity Address, Address Line One 400 Crossing Boulevard
Entity Address, City or Town Bridgewater
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 08807
City Area Code 908
Local Phone Number 809-1300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Ordinary Shares
Trading Symbol OSMT
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://osmotica.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2126709d1_8k.htm osmt-20210827.xsd osmt-20210827_lab.xml osmt-20210827_pre.xml tm2126709d1_ex99-1.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2126709d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "tm2126709d1_8k.htm" ] }, "labelLink": { "local": [ "osmt-20210827_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "osmt-20210827_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "osmt-20210827.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "OSMT", "nsuri": "http://osmotica.com/20210827", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2126709d1_8k.htm", "contextRef": "From2021-08-27to2021-08-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://osmotica.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2126709d1_8k.htm", "contextRef": "From2021-08-27to2021-08-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://osmotica.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 14 0001104659-21-112264-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-112264-xbrl.zip M4$L#!!0 ( &5*(E-[6=ZH10, )$, 1 ;W-M="TR,#(Q,#@R-RYX M5^<@ELPCY;Z0#^WF1/99ZTC5$!J-1BX7KW@DY%"Y M1(2;"78TUK&:J)7&I>RW&?V&*3(A'^#/AZ/C<9MU!Y2?Q"U<>2+?\=%MV+OS M?S^U#]B/X5B'7TYZW?#E\NW3,#P0ORY9C+K7W? K>6BE1]85>:8A!N9=<-5P M;'Y9>J.**^0 E4LE#W5O6IT$YZ3 VCA@?%@$]ZK5*DIV<^@2$6? A2C?GH*P0>I1"60[UZ0).4>(.Q"LR&P9? M+L&2!RM>#H\5'& <32A]K'J)=+910%%2+\--L!@*]5M$52$AW2J@W75N[B<, MH4*A&<&V5BW6*YV4CTW#!32D7%\)&5[2/HX#8^HEQ@'K,^H[0&,YH-H6GXHP MH7]1RRL8+VW:!TF?U>S[;SB*V4'G9+%G M2?L-QUREAOGK^6E2V8P3=ZS\J=-M3$QO8#L3.6\'$VMG M=9$+M8ID%W#*WM3 VLF_XAJ2\PN)B 9:Y9$]W2S_3>QN)]':P<_<"_>U1%8( M<<$A-^-:,K)9JJVC5-(L_P!02P,$% @ 94HB4\* M#'( "P X8< !4 !O)8P^FDT/3H>(4(C%B=T_6GT=3&^ M6,SF\Q'*%HQC;/*D.TW0F/& MO][/ZVP?\_PY.Y],7E]?CRA[P:^,/V5'$=L,RW"1XWR;U;D=[XZKGS+\8YK0 MIW/Y:X4S@L3IHMGY+DL^C>1QJ\.^GAXQOIZ<'!]/)__\]7H1/9(-'B=4GK:( MC%24S,46-ST[.YL4J4IJ*'[&92SB:_ET>Z+MJ]S5>D72$I%+P 9;KK)57%31Q M;?:.\(3%E_1]KO5H3_;%WP[/_X<"-..=%V')F&Y'_%]NY:?G-I]=^7E.Y\UILM2R272XZ,!(KDS*+CA:X.$+1,51Y MU[FSJ)5O*EMSQLVRRYZQR#,CT=&:O4QBDHB\3X[EQEANC(^G58O]G=CUQXR) MX<#%*LLYCG*57U&83R-+^D0W)I477+G#/.HI8J681$QT4,_Y."U/9AG^P-G& M>MBJ[,R2^$>ZJN/+DR,. 1AMR3C)V)9'Y$UUTW0+G:7*T285"CFN(G3\=3'Z ML="@WY7J/Q\GAUR<5;<8#FTWA.9+D:^E'.UD5Y5M,Z7JNID61%5;#.DUK21( M:KQ4\X4X?"PM7*5X;2F$ENZJHJVV5$VW$H.H:ILCO:YK#9(BOY7]A6013Y[E M,+^K-"V9\ZJWF#0(:&C" L$T!O/0T'IMZN_).I%=CC0BKWZ)W-G1L %ZUYU! MIVV]=["*@T!GB$.P_V@&H3K**TT7E&YQ>D^>&>^"J"USS8[-I(Y,4Q,4*19C M(""E%I5BKUS\8RNN[0E/][UH&$K7= !6=4 T65",V+V!F-3R$$A97)(!9X_)$TP5%"V .OFRI]2'PLG@D:2H?(F#:W[C8Q*Z9@0WKU)C* MH+@![8'D%!&H"@D-GLL7.8(7@ZB!16[H?2)DV.ZBJ!8'"Y+N<"!+11B2<5YY M:CS(Z"')4+IF"+"JTZ/)@N+&[@TDII2C0A\**I$"N0.1*0,4.45( -C\ MBV ^#)J&T@\RAE4[,+4L0%QT;WVP2+U'5&9;SEO>X3X(ECI[T-MCMG[F"^B" MP*7'G/$DN)2W-M!7 ;K+-0EL3$ ]68P 3!VWQYJI'+F:BK>(X MG=.8['XA>[!TALXM&8#--AJ:*" V[,X ."HQ*M1(R#WB<<>3#>;[11+U=!ZF MT"T@D-$V(;HJ($0 :P CE1HMYC/_?FQW28' M$ <$4+=#@",1A-I1_G&:TXCQ9]9XG6+&MJ))W,]8#(]<>J+43,&S8-6Z9:S#;ILL MBS @GF!W $65\H/:0#(&W=*PT#EY0X%/_*-S,A2=DZ#1.7D/.LM7%A0ZIV\H M\*E_=$Z'HG,:-#JG[T)'5'\ [-X:T/ M&1D@QSDRQ#\LQ;#KEM]Q]I+0"!Y00W(OV "FK>QHVO LAOLHZ@>+JLX_RA5 M _?>/Q@E\]/BM$W:FYM2$QXJ;6.]#4VI]@_&'>Z\9+>+O4!B-6Q% MI:4,#QB;O3YLRA@D@OQ=@E?HR@IRHW$(%"P.3*G*I=W M6TJ1G\J6O'*"@=:AG>RLJBVFZIINI(51T:8AHYZ+OW&A\?='+=>E2>\>&85? M/3 EKNH;,J?J7$\/HMX!4WK=%S)4Z+S>SYU-14#GJJX[;:IZMXJ"8*#+FK*. +K$K-/H-*T1@91"H]-K3D1$!XZ@1@EE7E M"H4.BXH&BR0((&!?.A,W#%525&K]K;?5LFPIE);N"@.K+05 *S&(JKO.P&92[Q":FB! Z#!F7+A44J2T_J9&'+JR=?_@ M8.UM<+#N&1RL0QP!P?JX.5")Z*ENEVER1H#"S!VJEVCT6%9I\0B M#0H8V!_8?M0AZ!#C9^W.8@$W^8$"OBE<7(D-2UD!G;/5.[MLULMWVD1!D-+E MS%C LUQ2KR%&4NV'CFVG1AT'2 M,),&5&686J^Q#CPLZNGG9GSYFL=O)$U_H>R5+@C.&"5Q>0?&]MRI6^_VO9P> MV^U7_!YD1^22-Y(5]PCBN'8*DAN>MIGUVF]?F>-FU ('4:!&=X MUC%RP1NLR/*\\ V?B8'8FG6\J:ZIW"]_8U@T5\"I)0%!8O/5L0X.1TKKD8C% M!J?IYVV64)+!79.F3]F1N6HR5#7S."\D>"+JO/]S57Q"_S\?L-EBB2$S3* MD3N-,;>!U"5V_CT6T+#Q519#&01.O?;@+[34$4B%>&'G5O#,FU=\A95Y3C;@ MO(O^$%<<#36O:.K3!\'40),Z6458^S*\"$0RTO_*3,VE_N$!8$OD>-QL,:@- MFQN*($@!;4&#YN:7$WRN#+A=I4ETE3(,WY5I:1RO!VC:TY8"/ @"XL!T!2T M6 A1H?1(P6=,G_CV.8_V=YQ%A,@WNK*Z_>J[:S'+% CCP^-/LS_+4#YXKIWU&BX[K'1(XL_[>_) N)P!L22[_+,X MW%/'5(.+HU_P]08&@>);W4*7@QEJ9H!6\DVT*@OTN\P$%;G8O@W? MW'4MML1NM4O\6N&,B#W_!5!+ P04 " !E2B)3+A&*XU<' V60 %0 M &]S;70M,C R,3 X,C=?<')E+GAM;,V<37/;-A"&[YWI?V"5LS[=-K%B-V,K M5D83)W8M)6E[R4 D)&$, AH M*1_7X 4%7T0X/J2M0^V3"Z ?9^%0"X!\.+= M.N71$U6:27'9Z+8ZC8B*6"9,S"\;7\;-J_%@-&I$VA"1$"X%O6P(V7CWUZ^_ M1/;GXK=F,QHRRI-^]%[&S9&8R;?19Y+2?O2!"JJ(D>IM])7PS!V10\:IB@8R M77)JJ#U1--R/_FB=DZC9!%3[E8I$JB\/HUVU"V.6NM]NKU:KEI!/9"75HV[% M,H55.#;$9'I76V?=V?X4Q2\X$X]]]VM*-(TL+J'[:\TN&Z[=;;.KLY94\W:O MT^FV__ET.XX7-"5-)ARVF#;*4JZ6JG+=\_/S=GZV-#VQ7$\5+]LX:Y?N[&JV M9UG ?L\3S?HZ=^]6QL3D4:]M)O):N/^:I5G3'6IV>\VS;FNMDT8)/R>H)*J]=W:\. MC,QF:?NE9JY;-:+V0;M+1345)I=Z:P\<%*%K8[L33OXSXX#IUF MI[NE_,H>^IXW=S751I'8E/5Q,J4\;^6[M3DR:?\TWTHJ$UMOM6N'%L>>[0?P M2L615 E5EGM9%U'Q0=A..^G6HKTDRE;4C!>,[R(^4S+U,=KRD!Y']W'9)GXF MTROK1>(\&7(RKX9Z9 *DVL7 6JD&E^M[JF/%EHY.#=X#2R#E'BKE"FTHL,MO MTP.=,^>U<\A=C*D[&!XI/$6 ^,\PQXZ@6M0X7 F1$?Y EU+5X#^T!%+_'9-Z ME394V']G1!FJ^ ;"^\08B/P/3.0>A:C4)XH(S1PE"/93:R#W/U%O3CP:4<&/ M%Y1SE_<1 >KQ5?9 ^*\QX?MUOAC\-T_N'L!>>. 1V"L"#,*;EQ*$$[6H<;BG MBLG$7O85( (GQD#VYYCL/0I? /4;D4"9[TS!61,^\B-YJ,"'3,>$%WX-[3$= MAEYA#@6/DJ_6RGP!\/^E1('1[QE#P:.DL#424; /,J4.7 J.,WYK*'B4Y+5. M) KY&V&8V;@IA<]9.OWQ8/:0^*D5E#1*PNH3A4BX?&(AC)LP"5$^MH221LE3 M0^(0:0^L*D7X2"1T_9%N0KA/3*&\4?+3H#Q$X/>*I41MQBRN'T9.;:'(4;+2 ML$!$YA.R'B56&YNQ8A*R'KVW"#0"*"DI2"YB($8BEFHI]QY'#V1FOZ&;@4R" M0WU-06A04'+59TA'#,U5DEAH>OOGE@G:#06DTAP\'X47AH#,%P6_]SSX/3A\ ME!RV5N:+@G_V//AG6RM3'SX _OQ3DWDRC/_[36&@D?)8VLDXF//KT-W MZE[))U:LUZIC?U("&@#$]#8L%C\*VQL!2,\O+:'4$5/=:G'XM.^E-H3_QY9U M]YS5]E#RB$EO2"C.0\NB#[B''[X%3D6ZE'!RP+MJ*$G]7/K2 8D5) M7JO$H%"]E6Z>92%%\$GOJ164+DH6ZA.%,R"[A=#:.QCLG0:OL4,9;H]EH,#\ MIIBQ?@QDFF9B^\3',P_G,85"1DD=@_)0@(\E9S$S3,P_V3M*Q0BOIEUE!T6- MDBCZA:%POE?419W:F_5\I9G;.Z'N9C/?B!RRAW)'R1/KA;X$_B.M,ZJ>&X6* M4M!8H*2,4-$X(P^-,SL<;KJ]Z<3M!_*,.R=64.(HZ:)/% KASW*BB-N..-ZD M4\G]&UXJ#:&<49+#@#04U ?>5$,^,H'B1PJS;T9V@_5\#VF4.PX6T)#\G" 9PDS-"D<&S)!1&S3L=T./D]^ M7U\*&@:P5L$&@O$NEN8R/&]_9 AECKA\MU(:(NIQ M2CB_SC035 ='FR-#*&K$=;J5TA!1WZ14S>U@]T')E5EL=[2&D'L*0-$CKL8- M2L4,P?K'?OIBIU^0?X4U^%T-B/"](G%?2!+';F%'<;47"5$>]B%[*'W4C:1^ MH2C\[\R"JOT[K=RED$95/.XB&7)'@??V &I8R8P5;(0H1\3<2CRI8FWMPK&5/JIFKT[OL'2*. M%4 #@YC;/@L%Y@,'F:9NJY2,'\<+*UW?929_,:SU,OC8(5@.&B#,3:L X:AW M2OK'9C::7&\>Z(PJMV!B0M?FVC;W&+YQ A2'1@GU[4M@#!7!NFB?Z+JU!]P; M@(LS[I=[RZT]\C]02P,$% @ 94HB4[8L"40W%@ CG, !( !T;3(Q M,C8W,#ED,5\X:RYH=&WM/6ESXCC3WU.5_Z"79_>I3&T(-N0 )L,6(23#3 X2 MF&/G2TK8 C0QMB/9 ?;7O]WR@0TFUY!,9I^=(PF6U&KUI>Y6R]G_4(LPW'Y/;@7<[W^OER[L_:^MK^T(-^T->6[W)#SW.KA<)X/-X: ME[8<,2CHE4JE,,$^N:!3=9+9KZAI>N'KZ4G'&+(1S7-;>M0V6#S(XO;U\N/((> M\8#)LKXZX@PK9%\/+D]FW;WL_K.N!4]06_8=,:(>\! A[>2U8KZXFP"2E\Q( M 8+/6P/G]EXXY7Q)C^ L,">]4FSN41E3W&1SY([FA 884=3RFIZ +EA_*?#= M K1&'7V9'U#JQIW[5/94Q[ A S:T",=B,G.,:LD89#B^[8EI]AK"QHQA4GB+ MT\##C*[GG=-NW->1(\?C!MTRG!'VU;5R<2^G5(]1$[X3_+/O<<]BM?U"\!U: M1\RC!&'DV8W/;]_E&H[M,=O+=Z6SB%0(-+>"X0@AV___R>7+$ MF65628=Y;\D9';$JF9B3MZ1UJ'ZXTHJ5JT^=WXN'Q_5Z&[[A4D@^_]#1I?(5 M+O4JN<2K:(F/@+/=C$<]9?A.Y8J![ '^\*]I P6G#2"-H%;+-MGD(YM>:6"? M]DJ5[>+N4^'61\PVX;]W9-'!59]:DCT"U.X!T/GP2K\*S48 $QX]!D;QJC.D M@LFKXI6RD@$0J9X]!LXAXM(.89464%H*O.>84R*]J<7>Y?H@?E6B:ZY'NGP$ M7<[8F%PZ(VIO!@\V 0'!^TK037X;C3.Y="TZK1+;L9EJY),J2BP3J KJ$S=- M9BO%P(_0\O(<,_NW, _8*F#C(FUQ MK%((ZCDBT?QX&LSCF 4U,>DALYT1M^^;]GZZS,^;!3AJ3U%A@:"AAB;T,3 / MD1G?+\!X^(Y_]]W(](^H&'"[2K1<[;__T7>UM_L%M[:T2]R8V-(N?8OEVW2@ M=M[DKA*,RWN."V-=V/?"!SW'\YQ1^&S,36^(>Y;V>RXUNN<(P#L8?6!1XYH4 M85N3CL7-MR1LC" %[?JL'3?"O.1_PS8+3V=+0PJ$7Q,K**26\&CZA+ON]GV[ M;D0 M7*BO26HSWEJ\0$\,L 6H<'?[]4^G;6ZS4/2Z=:[SR0^MDA:7YMO*^?'3=)X_STM-7IM,[/7@:/+U0.(1;V'!A_N-78(D5M M9[OR,G-'['V)N8[.+T_#^:1+[7]COX"8UNZDS[V.YQQ]7DZG0+POFV== M\1P8:*!;%RQ7+Q%'$'UGPWP3/'#ZZVO=(<->ON > MA[F;$V-(;;!(=<,C3I_HE=+VR]+^L0"SZ8 .#N)_R5Q'>&0C^LPH;%Y,>H3= M0D\B5#,SWU0!DSF5J,^I1%NY1\W >-Z93R:S8F1FIXO ME?>TRD]AAD=[0"F#619,9JC\NY93GUUJFM'G1T^:<&=C+]5P+(NZ$GS1Z*<@ MOMGW1#3!+1-*."/F@M<;Q4#[GAGU"H'OH*L<-CZ;3,W+3CDE.RW;< 18;)6K MZ'A@[AI!BK;AF$M4_LOWAELYK?#I^2HL,J;8J\P<4.$*YS;,#Z>M\@,PS=5: M@EG4-N\5P6,H?!&/,Q"Q<4O*0_+A$T"^M.@]EU_OIP M4*JL;)?*F#Q7V]8TTA .;+/V@!PXOL5NJ5@P'"02K9#/#UIE WX\%UUG;"_9 MB3N?=ZPS^T##E.EJUSB;.E<[$-PQZ_Q6@([ "3 M&29]57AEYC=>5KWU+$%I.]*CUC?N+G<;Y,?1WN3SF>\ZZ3UG0GK,7UI1(\/ID?ZK&AR.<'BPG< := +"(*4U\ M "0(M:=16Q\"26>,XS#\X1CZR^KKS5S,N>P)*%]@#2@H,K>P8U1"U?LBN >D MQ"2';X<.L\S6OXO/PW+]QMK5WS]]LWA(P4 F2@'5RF^7*J?ZMKX6#@:$DJ.) MF\@6XWE4P(+MXD[(?2^='\:T\(:^1QI'EZ18TK:@X^HT[#D$X*?*4I2A[#@0 M" (![<$INKF<6MF"Q ^^-+=O+XNC:^M9!6D1GX=*T6PDD"<8ND2$]&V:UXL) M*4H=+<0RM*UM!3W_%:.E8A1%.VW!4/>Q$D:=F:&A%^?]_C*_8$P/NO:I^.P9 M@V<5I^5X/52L $+>2(!XF)72M\U\<:,7GF8]2-*" ?_*VE)9:V3+6DM*GXE[ M)6[[\_E1Z?; _#357U+B%K![9KDKL?SVAO$(N0L'O"ZY6W1GXUJ9NXIG0R\\PKHFJQ_/.H*F@0K.**.M-1S['^ 00M[?TT@N(!?%I* M6621(;X=#SD\F1FL)*T??U 1]?HY*[WC(",TSE.]V%-JNR1E].7:/YZ4N[OE M5:3!Y^?,UF$1:AW9([N$/D5B?2K8=)>R*10]0.ES^90K].N]\1) M4]M912HR-2&PIW/:_97'+RXB&YC?S^N"OL=M\>KYUH:@ 9D5V MI8L)LG!".R=->D..+:<'X7>'6>!MD5,JKIGW0*;^$@G^7*UEF^B*,]*;$D/E M1:'#-5ARIDH6YM*57!)@+/CQ"&- !L(9>\/U-7#I75T\V'R?CK@UK=X5RZ9/ MO:,ICM4$C0!^MH*/NE^_G)V,_KH>EU<9QGK"9XO'@IEXY6J3NV/7URL63Y:! M5G]];5&!(TG XYU,:\ 7SBV&H.K**(*JVXX*2'W)5"_@G#H>(>HB-%<''\&] M)V28FLN:*CD<DABH 0U3Q&KI)A2F#@Q'S MSG"XM$'3X7#2,FS]D,17TA(_Z<:K#(J$L\6]I9OMCX9GWG)*!'B9MYP2MZ!6=\MI1;2?OURV4@X@YF^A_XV/24( &RQ#>;.+ M%%UZ-2S)+[V8P;!=).6+IO&" [6&-;N*!DF@NQE <5G) M)22(F^18:LJDH#RKC"2R@LDLX'R6\,>R@@\B^X_48&ON#]9PU*RLYW7WJ\/XU*^UV+164!=>/&Y^%F"3OA(9>N$WV$5BF9 M)[?B27Z)V"*M-O'2SVT27)\)IHONT&R29;QLZ<.J3 M_O;-)O@0)HB9\"A7Y.*>A #&L:PI<<88C$B_)[G)J>"(K!%0'CT4@.FBUQ$4 M;YA<&I:#'@BH#P-\/5^P*,Y(3(JU,>MK%AM08XK>B.D;,&//EQ#Y2)E"]23H M=!"V12AO$;P4EIQE# X5. +2'^&A+Z(F''\P5%-+:L5HX,M)O*FJ01$P6*H" M\L3:,U!57IW #9)!T6TH"Z=*O%2=!%<5<$BE#G4T]%M5)4Z$X[$ 4[] MINLZ 5?-0@6!A1M4#C=Q>=]QF8"I 0(&$BJ /X[T\LC6H&C)1$'$+6^!AV!@8ZMCGBL@.E.B(L/'T8JVX#Y50M8<(M<5X0@TF4& MOO7 C-QJ9#OH(1H.&T:@N$ARZUC^B"5FG$EJ*"8!@]?78@[/:H\45<)%A[T3 MPOK+!,RQT>FJRBJ(7QQ[B!2T(7"KQ2J$UB*BG[X-MA(J6X'1E?K.1S51%:D,-'3E$K[Y9,_8I-BGE]:^B-8J= 7?D &@EJ /?99,A['/;S9O!#B/26'M%T MWM U?"&0?.&55+PU-U_#!RM28>=<+@J)%,>(B5MW\&]&KI(6W?>DMMK M$5<#TJD*P>A"#TP'%I8!VY(R\8P*]+_K@VT_W@?K@KD?P )!UYJWRK!WA]2# M;0[HA>\(42:U91O@J:.>@ENFMM&C.#]QGJCM1$U+/HA*.\EYOY\_H!:^18]T MA@PL=%T(%#14]3N=NE7<#W@9 _O$?%0=#&U@C7N!&57,U,&A1GT*T-]G6!1Q!)TAGQWJ0,C6;RCUR;#O(C\V0F:*7;B5'!%L/518W"6W9E?&@ 'Q=U*>:<'CA#.F DY63L>-;IO).05=]L(Q(*X\"TRFZ(2%A. 8DZ(RC( ^5?YVFBPS\XN6^ MY4QR9_8 VQ">\YMX"MM\&@9:<@!BB-ZS6)'797H \U\(\A-.[ZG\LC*QV5B M1"P'Z- +C3/T_:TTY\'?X07C/N'@(?S FBY5LSCR>.Q2-^?H)IA+N;D0!^U5 M8GSI ,1B@+O6["X:B()O1RXG%X#&G11PLH/S0/A@3G52&M$B22MX)-@(-"D% M5Z*Y.H/%X.61$*0>@GSUARQ/#27F=71];680,;0@SQY9W&4E7ET(H&M/B %T M[94% >3?&."GQP"5)^5A9\Z\NEPRD6LZ$)^TXD@&_Q9V"]?MA;A(;U0$M#7P%3#O[4LYY >!X!QZ/8#,SG#*" ME0H80;0L*@]IWFMQXA<8U+9^I=\+[.E@=W-,*?WG9K& M\_^^ZBK D"71"S/.G*U["Q\C9);@\HB:ZF7K+%=6OL[#F0^XO @PZ[9")AJ1 MHZ6\I-T]K:*\I$KE85[2$U>!IB3&FSZF.#[3^M[%IX=#^3FD^!1;?]P5CY3U M;\36OY&T_IFN UC_N]]/EZ;RXR5D-<1=.90GB/K3&*1CIO<.&_)8FJW8?P"3 M#?13]1S!K'WAC((,W7V1R3VBLQE6@'FAIZ!^Y0C!WSD2;?^6;V;X";JF/W=A M\CWB\_+EUJWCLWKWTV7S%_1GYXE)?X*D3 MSH4$.\7?[][&XUN:N=K!M/I#,<+V+@ IR (Y$!R\ +SVPR4Z]\])R^R'=V(P MV[]_NN(\),N7<3,MN(.F:_$5M"B\S^O)ZNHLYC\=VDJ!*5EI##GK@],5O??O M7+WW3R39-6/6_VB9_;Q'5GI+SE7,+*ODA$KO]3AH+UY5!87*X>_+^5)R_[[0/AY\G M?#"^_+I]>^*>#/36;JG;__:A0$WMXF):OZ[L[!BMSC=^4?3,5OG,^L(NQ^,; MZEF?3AW9_'!L:%]OIR=T[Z@]EN6/U/NK^-60[;WZ]\/IH>V.CAI_?+T=[+6[ M1U)^+OR]/OEV5\]_K+\:9WSLUZW0X_.6Y/C/RZT*>>?C)NCL_:V\(_:IY7FZ<'U3?/ M'UT6_#/V>?C^D$YN>N^G7]Z;1X6#2<'ZH%U; 3G^'U!+ P04 " !E2B)3 M2#T8J@+E[N;^]O#@+ M_H5?S\*?+ZX>;_Y#GE_^YIY9-&ASTD\&#PJGQ./_?!. MJ&D,X"O'& R]RN7%U>7MCZ'1,[Q@MD[G5+DXN[HL=M:<5U;)#]PN<8L MCSD'F]N'9_@./CT_WM_==/&!+W[QH4 "Q6#FA]!BV-BP=(;ORZ<-PZI8;$"U-WC.UGT-_N[Y AS73X'Z)5PEOO@L:OPUWBVL>^X/K4\XME\OB?? MT8;493";3IYQGN[ 86P$")F".GXN_CD>4J<(_#]]BX4(JP,Z.,:^&]Z0=#5F MFI3\PS9UP!A0XO[^.G-H)QX18>F:MI-")G]9@M\)[?<-TX"9$2_)A3BG^#%: MX_'1U")CX*7I=PC5_O(-)Z3!#.[@.\?V!T/^6T0*_,S@'>^-&,CFS 5:P/<: M;1/.+Z/=?0#>H8P*ZX8!N>!T!D8^..',0+\ "/]I"@*&1FF";]*./$? M !@QB9CV_5.M("7"=7_ *9'[+A3]'EQJ.52#<>.*'1*7B:+X]!/H_,[3$88 MU8;(IZ\ &O\]6"%GB@A-'HYMX-#'1_#BJZ$!-AQF'@&OX#E&.PU$(T$I6$8(+YM30,.)/$,RX<_0./\R3S"?F@FK. 5 M.298@3MFFM$WX)')6CQ05@1^M1@0"'G-):^VZ8]8]$ M&"A8:^Z:EK^SD$86XWP=,"5B*\'L$IFCTX^/KFUG?,KY_G=J_OD&,DR^@HX8 M3[1"[_!-;T)TETLN Y/,$=![(]D&)-2 MP;@9*R=]W^%$"16@CI:(@DTU/@6HG(*8?+=]$U7%GUP/!3H88(3A?2U4GK[G M>L!Q7*P!=&+:8 9[U*06/F&3GVH3E1;KK%#X)9@W,?'Q40K3X';8YFL"5WVJ M@8'UD)4"X$!%XKR&Q1%3;<@_!].XX.SA>Q'#S4=)9"<<-@*FA7>.C^)1$L!^ MXM F\01VS'=0<89SQ.MW TL#H+E#V_&8-;$:C#JF ?B'5ZH_PK$450;&?@-[ MVX'R%PU;?HP<;4@PLO$2%_30 >"7B 0>0LQ^CYX+2@J (U/0-$XBV2 M"W#O0*31H -"AAQ;,W(1X"HRV"$X"97%45Q]?8?%@+M(GS$W&CJ2PQYPMQZ3 MXO@HR6[@B5B:,0:S&;%;F@[ VK%-Y[HYA6)A@*;A?,-O5-(@(N$9[1N)01W>!QW3P(K3 ]U/EQHDJ2^0)'%*8+'8(OX#8 M @V!A/"BQP(%PV5?.2?N<&P)V/,<5&&%'RU'F/(S.#R!FX06!L]"4IB&"/0$-S5-D;?!Q@@5L]_GX_1D/B'6!NT]#[Y_Z3K@!-GAN11%)05 MF].7)J3DSN+@\)=B,9A^,2$++],^!(<@E--D4 4 $IVY(-R]";=9MC?1QA., M9.,A@:@LA @F2S/9@G3A]@_,'CST2@T3(T&@T(0)T+""HO)'XT"U<&J&(9Y^)/6J#K"V>!C=!MMX=?5K5%3I4[9&#M(SW<4@ M2$$6 ;E 'D%ZSS)#DO[X&X*-;IR.7C#3)0XK F$!*[HN=0SS+?H9H<[.S4+$ M#E'F'#\V4,4S:\.P+"BQE,/EU 1L?SLY <^+ MF?IG\@2F\QR>_\M'0P?#GF."S<=/Y.0D+)M>W-S]/EWB//'L,3RBCKUHEI.> M[7GVZ#-IXG<]\ >9$W]W95+M3Z( &)SI 9055I.N=,5S?DY6T,J^PZM&=HY^2!CEB C0<;%ZXD7SJ+WL)?)F2Y. .\9*"H!Y['GR<] M!L(+8XXYAI. -C, 150FT9(@767>E$D($?* 8&7DO2*U9&A=T=/DA%SHEH_V?*DK]OR/N&"3_&\#XS#7-S1N2NWO[0AM0:<'!&!H3VB0CJ^?8Z MKO'!U_^BCC;,\D\0X.6C<)(1>P>%2"D%].TUCI>DLL]9QK "AW3$ M:#(-_.08KUB GD@ N8=_!@&8WU#ACDA7X\5"I=-I\)*!R[VHY$Q)X1XP"SP. M3 F'^RSV8[S8F_X( THT6 6])$>3A5X':F?T6T^:SWP5A MY.RWF*3&Y*_'9G^)$G71]Y/F@RB"G7T#2/Y'QA1AG)QZ&L*BZ"L;D_ CB,L= MC'9!N;D\V$UF,SF5H_0**$5>Y09W#Q@"1X)_8)"!C2T9\#\[QFX-G@-'9N!\"#HQ"-\CKS(1NR.&G* $):KP97.+#^] X3N M8_$'YAIA59#7 <-T;#94QT>3#)2/J?_ Z(!%PH%#S'^#=\D7@-R."X]1NFK6 M:5[4KO0-%TW:Q+P<'V7;E] "9,^&91/N_'A-'WT 4?4 3^2+VBA:<(E+*LEI,", M3G4@()TPJ'#!\A.[9T9O>S;QQZ@L(1"#;S7@)( ..XAX0\^[^ #P3.R@B]9H M@6)/JEG; 04<1$0@FUROLA\: ^U.,7@+VV6 04WZ?7?#F'=B#U7$'CSV4 \[ M]BBC>U5P/V^ROS1VUR95DNO87;M.)@FO@C3F\=$SYC%WJ:]T[NJ[,^TO492R M%XNK<@-E^RZ8FXER=X?H%Z$%&F/C _\+Z$L_[=*:4_+QTKVZOR77M_?W3]V; MF[N'K[]6Y K_^_FI>QW]'2FM0&-C3Q8=NZ"WHD\8#>C>$ &2?SXGR[3E8Z__ MMVB"5^;P/K)H_8'FJT3*[.4FN?P3U_@O"Z:9+.OEYG+^8^>@:'5TYR8J=>;= MR437CXB!AU\K:F7)23/F"%"R(,"X;%-?B+8K+*=967&N+-/ZD0E/YJ83+1K= M25UO8>0M#&D!O+"73'?V\FTM\5M,P#% D6L?X6AE=&2KRX7HDHL(+@?X6M)6 MN4QV(^4']>Y0Y6/0BAAS=9DL5/PVN+Z#$K+'9(>>D+(#E[)EB"TL76Y".-,4 M6Y@8EG/U<4)AB^IG7SBI"%R60ZD4&R;F2(2/P\2N&Y9)TGYML?'@'N&PBHDH M@;O5^&];^8A"<+@YO#U@M\V>\T:TT[5HQEC8J #( .+ L7U+QU2L[7PFSJ!7 M5>6ZI-;:DMIH?%K?\'3Y;OL\?8=I])NLOW@"[9W#399XF$'@JRU M5,J_AX;'UDC]9@%WCXY^L;##7-B!(*MHAR6L*-<:2Q24TS!/ M'$S\"_NF%)5W3EWC:0)8S>?'"F#7UBLULR* J+*]5%W[/=*N,& 6+7Z:!^@R M%?A,]NATI%:KE0,>%N?:PT.R MPOR[+ BXDCGA<^WABT-U%IT#@'W,&@.+V#.9A$>N M92=YUN62_#7<6CS1K#?R&2\/"'<*!-F87]TPJX$#$]X1I&A\S.V+#SI M9G)4MS:5YS\,EJA)';DM]%V9]9W F[ 3>Z04=B&"F.J.F6-(@E83,F2FSL\0 MP,/]5\?9TGU2[S< %9&&+V;&F.?JDE*K+=&NM!UQ.70Z53=%J%2R7]!H9?NZ M02G*=:MJ=NOC1Z,*GBD]SQ08+*[45;N$]0_+3L%=3;D$C(+YU'I'JK>%\2\[ MG:HU6=C^DI-H3N?(9F@DK/]N4%50JM7K0H65 M684)O G5OS\ZH2&[9UHGH#RNNL%"*4S+%P@YS80>"K-(UFT5' M3)L3U2/.F18+V_^%K7XCV XB^?KSFF;WBX9OE*6RFW>A&K9%[#ZQ>_ >Y7\!>,PA?<.BEL:"K72'83Q$>VVI M]9_ F[ ;^Z$/=B6*R+ 3P<[J**S(+*KM'1\HDBRG^B>$CBN3CA-X$[9A?W3" M?H04I@V/ 5^,B,YZP2%,^+7.^@R>U<,( X_KT&SW0,[I4)6ZU!()JG(KQ;W# M6U5I ]MU4FVZZX!9JLUR\=63Z1LG]Y*@:D?JJ =?Y+BS-'O$B$=_L+C.':SC M)#[H-[1'!\$52DV<_B<,RQ[B340IY=,(NQ"C+'(I3+)U7-P,D\^FL+K4;*5. M'A-[PDI&INJ&Z+0O&\.V0"*Q"5SP3+EY9D^V@&OIW1R" U?.3C0;4D-L"B\] MG80#4'X2SPJ\[3O>1+JX M;/0I645QCDDXQ-[&>DU<&U,R81%X$T9@/S5"F8.$]YI)L).1H+4X" ;(M4WL M@ 1'&(12XTT8A++I@Y)%!7/RAC=1OSHW#2(IN2H;-45%J/0T$M<"" J)CI!] MXYE-:]Z2'Q<\AR&"1A#1 ))+ TA3:C12V^>%,2D9G40#2/E)M$\-(,*Z%]'L MT9+DCKH[!KZ(?^,G_H[XWM!U @2Z1IBJUE(ZDU)3H5\-U\<^>6+:P M(T(;"KSM)=Z*B!4$+KLYDCX44K9WDH)#;7" IM;'.- M:+7=>1U;WNAPA0-6W8P.7<&(JS)BLRW5&^*$];*3*3,,%E0J&96R ^Z=W& C MMM1NB&=:BM12=^B$U8V=M*Z>-CYR!1);;'F32;&N 0=H!=[D[Q'=]GLF6X^( M/RW$F7G,%]V_TFA(\L=[OD-2E#:A&I838Y(OMC.CQT;5MZ3$U@^,_7/Y(D.0"">P5=CE@8:I79. M?L?^8IB4G)Q$TGQS]WL$43#/B6>/X1$563S\)F+\)G[WOLL.H*RPPBPUEX1& MS@"&]\DDUQNM])R\O(UAE5T'7%CMG#S0$0NP\6#CPFO)E\ZBM_"7":DNS@ O M&2CJ.8S^>=)C?=N!,<<&DB+9.NKX*%9->*KYXY@Y%#L[ M@VCK>JKF&IQZNYD5 ,S$&S+B&C_(",8>NH0!_#KYIV^%1^V"+TQ4654V U#5 ML @VW+"OP"O]-,&@)KA<&ZTR?7M_?U3]^;F[N'K MKQ6YPO]^?NI>1W]/>S 0\)MT[ +_1Y_.R7=#]X8(I/SSXKY%9;%LPQJ%!5CO MW]NJ7,NS'G;]B+AY^+6B5N:,-L^=G9N\67@_U<)IE!66TYRE\P=YK952.A$; MOCC4H'?LWCZ:T%P"BB09C!$EDNP(2;9 M :Y>.,^X /+ ;ZFN-X8KF:CB/I,SP_JW:'*2J"MH02*!JTH MK*TKV;NXYEV0WX2';O>% L!%@*\6P)\SP94>^/N\97O&A:;U\B<@QB7$P-Q M3J)X1#7D(4V%LU[G%'-MJ.HA%8="-]F%ZO-9;(KF=5[A^81\:.K?L:8)F: M:_" M1W_,?V^94'X6:6L.\]$H@M&VH2Q+MMV\&QHVT%D#WB>&Q7>' M0M!V4/:'GT0O5&F95:G FS!!>\\3Q2JB0F*=]1.<[VW%#?;<*K73UN1:V] R M+9.K7I=-P@0RW[N0RAYO;3OX)L&)&%25ZO547+ZA8R $@8LG\+:.C1*T/4#: M+NR;+#+",E[']L<3LG!PAJSH)$#NP%_;+M]U-[!MW46LZZ1J6)KI\^UV\ ,= MV0#_?RG?7 -_&Y9'K8'1,YF[3"]+3DR]+^?Q*%*M_>'F^ITUP_M"I=(94T&A MLE-(N#N"HW?,,I2L/+[08:U1MNBK8[LN-J'U#6_UE-JAGPZH*)+<6..@_TR" M%7_ZVJ&1:8UJ@J#0WE-HO:-9M^\^;-(=$1Q=8M-0YD:*9V::L!R)#)C%'&KR M?@JJCPS+<#W<%/W*"/LQQD..5KX;9J>JF8!F659%>T"9VP,$WD1;Q=[S1+&* MJ&0Q,AX1ZC+J:$-N@'3VRDQ[S$_0.RCK W:^D3K57BC1,BE1@3=A?/:>)PK5 M0Z6N*5RQ;LD]02%!(5(=%=7BO M+,-N7./U3HDXV%!@!V=66H.U V11$VC@#5"I'@51C"P9F42Y6%!(E(M%N7C/ M34.ITR-9P'^EAD5LBQ^9ABF3Z @UCD)XT6*I5C;A("_,@%*SMME[;@65]B P M%Q0J.X5$ZD1P](Y9AI(U#2R5-7F,\R55TW;=3^2,&.'=>\(W7HT!J[5:UG[4 MW)WC'._-/C02B92)H)!(F8B4R1Z;A3)WU]\A?S(W;F(,NNMG#B#06<\C.EXA MZ%LK[_G;J>XB19*5-?CCH#NS1)?CBEJIU/.QM7'O/CR^/ R MY33TZ<@PWSY_-%@JQU'M ])PM$O!PBNQ<"<=[A]29 \QO#=D#K%LZV32_5 = M4,/":!ZC>N&TK6Z2E4Y-!(LEIY((Y\M.H364\HH!>RF\E\'ZWDM9 M*;QG,JA(ZCH;)TO8LK&%]M(,5RM,8@C&7)4Q56#,;1V2**A4]DX!0:'%AYT6F*,A/=:W'19V71"/_CB0 M,QVJM8;4;*R17"EY]EF4.DJ&MPSS6*0E+*/1*]R^[19#@ 9JM(O00.4MOL]Q M0.YBZQ.%LV?5'K-8W_!$F]GJ6<\U%,Z6NY@6P(;OL]DVV,'_.8-&3)ME27E9S1N G5 M<:CTJFZ*8#GZE8=*JQS]RQ7DZET79@&2S $A1[=C.R,*?;3+/%[Z_$K("%O( ML&R?!7_:N#546U*MGF,C[&&8P\W327@M.T&F/-,MR]%(>"N'Y:ULGK?SSKU\ MQ-_ES;Y4+N_Y#KY' &Z7M,+U_O9,IPKF<5Y=-Z M?40#Y6NQL)W7LD*<5]\N?O;2 MO;J_A<_!?Q=/R\\THL[ @%GP4?E]HC]=%CC)-]9G#F9IJ89E96J]X<$U#[8' MX\*WOUG4UPUTF)\PP@J2FOX350!:.)W[S>, GPK+#&- MN'AN#HV< 0S7>$DD1,L_)R]O8UAEUZ$]0SLG#W3$ A0]V+CP>O*EL^@M_&5" MJXLSP$L&BGH.HW^>!*<>? 97!=&>!+29 2BB,HF6!#TK\Z9,0HB0!P3+A7\V M(K,75Y<9JK,J;@:=J6 "/[;N %'B7_= 8"EU0SP(\3:I; M@%3Z:0- S7 2MSCD^O;^_JE[KGQ!'F'3L@BQ% MG\[)=T/WA@BD_/,RMP0M%,2LE9GYY>]M5:ZMZ(9=/R(:'GZMJ)5%7EQP_-0Z M%CQ/[B,@F[.$^F!_P$K'V$5\].)0RZ7<1)&NQH_,1PM_<86^3%?_PW>]T%*O MC)B5Z)-EE?*GV=989^'(?RVA V#76;V%^*: MJ[@6ZU:LD>G;B) M*AG\7E%XA0$7ZFN,\]8K#QS==5)O2.U&:F=:3G!GR\[A8;FJU&M2)WUW1TZ MIPSBX6$XM55^DQR\<&/,_/>6"7]GD;;F,!^-(D1Y2F%*G?2>^ *8K62]DI7+ M;_8;-;TWXK!79ODK'ZVP4TU4=4F1<]T!<$ -:-6:I+:+V#ZQYWC;T*T5HIES MAWBBK>9Z(\63/SL]46U)' M3>GK#=U=)\BT^*E,&R%3RM8*"JULP+\[$.=P-_+T)L+@&N30*TDEF@7O+9QO:;6D=CMUC,:V=:J@4RK%W9 E M14VEQH1G4AX:"<^D/.,)K9-3T-IJ%J]S-IDPX;,;N'<-P#V13Q6U85BS7D;J MZ]R6>FV[_ *(@6WK+M)()U7#TDR?;XF#'^C(AM7^E_(M-/"W87G4&A@]D[E" M-:_,R*VZ5&]OUL469%K!RVDIDI*N:@@GISPD$DY.><832B<832B>7K L$J\W.[G@D!5_X\,Q,$Q8ND0&SF$--WIA"]9%A&:Z'F[5?&6$_ MQG@8T9S-*/O6KJ1(G>:&CI'<.^15.U*KO<:M6Z)O4O1-BK[),*NJ2DHK9:A* M89,*:=%G+J..-@Q.;F>OS+3'N"WTL*R/TI&:G::P/JM9GZ94:ZQQD9>P/L+Z M".L3*J*:5*OG*DL[T[A?N;P;C:GA<.LS72068?NB MC:WL=*HV.E(]?1R-<%'*0R+AHI1G/*%T"FY*)UV M1^HT-Y:]+5T/P1TR)7/CGH&@F6UFSY_.>A[1\=X@WTHUV>]G+:\NU413P?'E\>)GJ3.C3D6&^??YHL)0?4>T# MN^%HF9?P[ \U"CQ'5552>U0.-,:':-X;,H=8MG4RJ3U4!]2P/IV9=OH>(.&[ M+9[6KHN OL3T:73$AL*RTP@4X?[1:'%@,X$HPF-9>*(8Q!"^N'(36LFX($BJC9&3"?8/IRRJ$^UL>"M4:I7.M1+E$ M:)TU,SN-=&*WO*Y*P2?3'@6S!K+8!Q6D75B3\%S#B M.=_U+/PA/4&D]*J6/-MHVB40,+%AZO;*FU$X[&CL= \\"KYXVU@7_ M@7F\E3!(T8-O,G;8$"]R?&7+;FI8$IH5>)'/0'3;[YELO66G+J(N;+YX7T-' M:K0_/)PQ!XI^F D6='HW12*U/CZW5Y!IVV126Q]68C=,I)7]E>PQUO$PMC/B M,EZ+8.YW=5!;:GY\L6-^_%VZW0[W_*X <$C<(748H9[G&#W?HX!;XMG!MT/; M!"ID)N[SR0@N<>A;)AD+2 >*A1WFPLJ9G-XCHI6W>CFOL^J*NH;&0[<;P_0] MII>O?) RG.M91>6T5OQ>I3WB:;&PG=>P>R:_Z6T@N^Z\5B[_S7!Y3"<49J4# M%CBG+LP5Z6=]OGX60BD6ME<+*Z<:W2.B"4=U-_I0$%L1,_3-Y@H#A')[_RV>6!I*F MGI/?J>G#ISHY.8FDXN;N]VCV8,P3SQX##"J*9?A-5!1HXG?OMU4 *"NL)HVC M>&X.C9P!#%=MR?5&*STG+V]C6&77H3U#.R@ZC?YX$+?Z?P2=!#"W__U+VYN7OX^FM%KO"_GY^ZU]'?TU5."!U,.G9!E*)/ MY^2[H7M#!%+^>9D:[D)QRUK)F%_^WE;EVHKNUO4CHN'AUXI:6>3%!<=/K6/! M/=8? =F<)=0'370K;>V.^.C%H99+-7[.7%?CQ\N!+;^XXBY+5__#=[W0)N>U MXCRHEV6R\J?HUAAKX51 F45JC9!D(V(V#?B:8G2#1S.BZ/CSLB#;$I7-4&7/ MI3@WK*TKV;NXYEV0WX3;:_>% L!%@*\6P)\SP94>PO]UBO?-2R6/M@Q-T$N M)P[B4+]<"FPS6N)P2++UZ* 5&\@TNVZY!L;V\[<.F4Y]<(&,%.E<\ZL.%B, M;"+QL9N8X44>@9/IX,$=V:A^MZ'C5VP&"?.\M<82:=YYFTS'CJW[&B"49EPV M'B64ETHGOU<^7F' A3H@X\SWR@/'Y_DVI'HKM>D^)[BS9>?PL%Q%-,NUU+4Q M.0&>,HB'A^'435.;Y."%6VCFO[=,^#N+M#6'^6@4(],LM/G<&PE\U6-:E9SW6GSP$UJE55J=TJ_LR]O<-;RHX5 Y]H M^MPAGFBE[QLLA9W9QN5(]X:&[5W6@'EMOKA:9+"*3D4%2Z<$N&4%,W1BJ3*FSTEO+R''50NKVV7;X4;V+;N M(GYU4C4LS?3Y'CCX@8YL /6_E&^:@;\-RZ/6P.B9S#V,E*JB*%*SENNM.0>4 M?*PJ0K NJ"O"_/*,)S3=MC6= MU$G?DEJ4GBMSL6KG[QYG+J*,-@Y/(V2LS M[3$_Q>V@S$]-E6K*AD[BW3OD55M2JY&Z9UE8'V%]A/59EB?4NM1HEC,1G6-( M5+F\&XVIX43'A29*GX=!Y79-:M5S59D')"-5M=F49$58'&%QA,59OPL#O+?B M,B][TCIL!P?[68.Y89'('Q>?/Z[+'4GN?'BOLZB%[BR%JVJ[+BF-XDDL:J&B M%BIJH4+3;;&OIRYUZL470W=X4_D\E^PQ=L9,.WTZJ^C77\+8RE*ST]A'8[LO M-%(:-:E=*YY$8N^+<&V$:R,X.ME4HC:E=G,WVK6*J(S?(5([/[%-XS.52E6CIB*F^=I$1-*QG>59C+$-RXLN5N235UL^PHR+1: MHD5.7Q(@?.#RD*@FJ:W2><&B;"(4SUI;Z7@?>[W>'A0C_5MAQ'# MTNP1(Q[]<2"[/*IJIRW)^1XK=2#9_F9#:J>-@\@Q+\9WF98U=ZX3NSQVB2<4 MO$^R$%VT"Z?;834_LCY@CRRVE=/L]L7'45N2LH'SRH0KNFY_)[9WBCI0B4F4 ML?-NVV(D(F"A=M;C:4E)GP:RTQ'P+/#J:6-=\/'&\T5:'):<:@5&XS,0W?9[ M)EMO3:F[?0N;+S9P+5GJ?'PX;@[T^M#&"4*]%\_7&Y*2/J"N #HMIKP%L=Z5 M*JE1_S QOV&96MDKR1YC'3]B.R,*]LZ+O?%$=37=A%D<@Y=N9T/0=JG9H['# MAGAK[ROCSHA$+):YB2&?5-\2Q\9D4JZ /)]8V&$NK)Q9YSTB6GF+DO-ZIJZ' MU!I@E9)@M1(>)YKO.,S2WHCG4,LU*=_S1?4_?-?#@^L.HVY0:^=ZQ_UAU"\W M=,Z:P-MJ\.VS#=D[GBA( VVD:IE##'&=\M*W$?TM<4!.\:'AAH&9)!L52?UX M6]6N)AL%B0\B32G(+!*<(L$I!&-N:C3C\I.2ID8WT;L\9@YQA]1AA'J>8_1\ MCP*>B6<'WPYM$RB2V8E2J^H:VC\,*P;P_0] MII;6Z5_*KGM9S/7.I9,YKY?+?#%?*=$(! M #I@@7/JPK21JM;GJVHAGV)A>[6P^E>W=_"9_SOXFGY>4;4&1@P!SXJOT_RI\L")_G& M^LS!'"W5L,F56F]X]-6#[<&X\.UO%O5U ]WE)\+Z=XA-?#(M:FD%-\NS!%]CWY18,_490% __MY,36"0S]<_D"2*'FT,C9P##U5URO=%*S\G+VQA6V75HS]#.R0,=L0 ;#S8NO)E\Z2QZ"W^9 MD.KB#/"2@:*>P^B?)\$)*)_!3T$,)P%M9@"*J$RB)4'.RKPIDQ BY '!-LZC M6719=N*/*'AU^?#X(37^X>N@_7=]U[WRX.+NZ+%K2KBZK=Q;QAK;O M@B\*[[(?&H/G)Z4EP^JC$L+^TD\;@"AG!1.0!)0K44X)^MPN7HSPY# 7YN.+ MRG5-BS%?$!>LAS8#+0*\+Y\V#*MR^3)DQ(]-QQA,!Z<:T6++H24LQ_%1/S8= M;FPZ")*[1_%A&WF"D>O 0/WR][:JM,Y=,C1R-7OFM8S'5YJ.8PDZ\W ;A[FK= S%!VBPSU$1M- MZ'Y\E""\;A/+]HC%-, ;=0R@483L[T,:8'QJF%DVF[ 3SFL$UYDX,(CKFQX7 MX/#,4!B$?+=]4R=#"MS58PSH-Z0ZG^)E0B1B:[Q?/F9LG!=Y2P=>!@A."2P7 M.,ET;<#-&P>_!P+ELKYO(@N.X5U#XZR%K_=]SP=9R8(S8!,.*&>E!*0A8X6K MY7,"SWH^O#\9*>+#Y$ S*T8(=:./;J0+Y#?ZL C+ RSW'7O$IZ C% 0W0CL* M_) Y#!:B^[P_@))7( SSWG#H/@!A.UMCY+4UNWHZ1>ON1 UT)XID?]1\0OF0 MN4I3,WT=R6X$_+ZX:;/_CZ:T6N M\+^?G[K7T=__OKMY^<>O%466?ZZL"M5''M_\-".\B*G$1%3\W="]8;RDV9@Y M_E7E/U=IJA2;CI6_!1+NSIJQ2-E,U(8$!MEE'OQK&A!*F/ 8"ZP:Q Q&H FR M[%Z& >X^7Q-5;O"7X97C(SRX&=4,;M$D&G6'R&8:8SJ'"[00**;324"?#.9G M(XEWT;U*5]T!,4QO 8;!LSUBXCA@HL$MT^$WH#1S/6,TZ]^ 8U M5BW7VV\K,%&8D= W3L0EP>?3HG(;W;C9\KI:CM3B!J_9RY M/61*$X3ZQ:4F(U5EY;UV\:3*SWGE2N,!,&8+_?]K:PU"AM9#KE[:G:2H\6N;;C'>.&3_TQ S@*)"8,%J< MB!!>=P>OF)H?G# 0)"W&$'5#T GBAZT-^'V0 L$X%#W!D0&2Z-D6/$G?@@#2 M'\,:CX]^:LKXJXDB&21N>@R]4'M@&?^%^;X/F17EAX+1-!ZEX!8';6@P]%7# MJ&,R-O[J,%@JCL#S1/@9MT*(F*-XSDO;Z33GS3'T)@2KUB T^&%@@?\Z/.O M>%U?*\)[P",_3!+G$A.3[J,TQ)L]/!*<3A$&F;$EA.ZT^> MP+&2*>Q/&R<+P%6='[8+Q"P^VM07XOLOSL!$W!DF:,5#1&!D6==X2BG8Z MCA[8MOX=U"0/LL,L\+S\C X!/ R#">E .X?Y98*E+F= N6+EB4!4R X;XQWA M7 8,[Y1T<0+^U21G-)N.GWX'QPT23:AM^X& P7>)G*"4'":Q8) ($$07D]9H M6Z)%3I6<)BCAW(Y%HSXU'/**Q?X(PAF(>@P_QD#%!F)Z6=,O'1^!E@'K!G_O MA+!,%9=JO0VXU^F^K2U"6F_BQ0%TMSBIT#)H7G(8I9CP^FN)& M$C,C?_H''PZ^KC=^CA.HO@V"#N"\&-F/:D/RD*O735ASR5C%=!0_]I)S6XB]U; AU)I77*"+ZA-Z?W3\^ M^J=OL8 ^-5DBJJPJW,5!>'S+#R*6T& *CZ*I#8[LS/N M]!4F>7(D+X14+I^RC1CGQ/Q8+YSLH*I#[;K4ZFSB5I/"BT8'Z?6R!;W>B1?( M:T#HIR:ZRPQW.FLWDP'):AB?[O%)A#>!FTNFO-SC(W1SIUID S ?M*5S[*I:W22'I;C7I<:]93;+OSSTO73+-+)]1OW27'? M5N"^:8:C^2/,26O8+?5*#9.WQL2.;."_\L_@E%WSNV,\\HU7Q%&B\)R! -GM MD_^9+M\'>SO0.\3[R?FP*(?'1Z&GC5TH.U%!+RU?+,06_64W VGQE4$3O\S M8@_\R8D*8470<_1QL@X#@&#_9+S%<#)HW(>'-0)XQL?"^$SE'*8=0>1&K63I M_*=:HD@Q3C2$A3R;W&46]73P\<-]9_P+@,%W$MN7<*;C(YPJC$GB-5/3AK'Y M!B:^1])U;7;SALE@&S>L5B07>CM$[Y&'(SK3*-<_(XYLB'V(>"L!]R MOTQ[V7Z9S36OG%T]WOR'=VO]X^5?]_#A_P!02P$"% ,4 " !E2B)3>UG> MJ$4# "1# $0 @ $ ;W-M="TR,#(Q,#@R-RYX